Stock Track | Recursion Pharmaceuticals Plunges 5.07% as Analysts Lower Price Targets

Stock Track01-08

Recursion Pharmaceuticals, Inc. (RXRX) stock saw a significant plummet of 5.07% on Wednesday's intraday trading session. This downward movement in the biopharmaceutical company's stock price appears to be influenced by analysts lowering their price targets.

According to the reports, KeyBanc Capital Markets reduced its price target on RXRX from $12 to $10 while maintaining an "Overweight" rating. The firm cited an average rating of "Overweight" and a mean price target of $9.17 for the stock, based on analysts polled by FactSet.

Additionally, Bank of America analyst Alec Stranahan lowered the firm's price target on Recursion Pharmaceuticals from $12 to $10, keeping a "Neutral" rating on the shares. While acknowledging continued uncertainty in the market, the analyst noted an improved overall health of the biopharma sector compared to the lows of 2022.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191372441?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191372441","market":"hk","top_or_hot":-1,"title":"Stock Track | Recursion Pharmaceuticals Plunges 5.07% as Analysts Lower Price Targets","media":"Stock Track","content":"<p>Recursion Pharmaceuticals, Inc. (RXRX) stock saw a significant plummet of 5.07% on Wednesday's intraday trading session. This downward movement in the biopharmaceutical company's stock price appears to be influenced by analysts lowering their price targets.</p>\n\n<p>According to the reports, KeyBanc Capital Markets reduced its price target on RXRX from $12 to $10 while maintaining an \"Overweight\" rating. The firm cited an average rating of \"Overweight\" and a mean price target of $9.17 for the stock, based on analysts polled by FactSet.</p>\n\n<p>Additionally, Bank of America analyst Alec Stranahan lowered the firm's price target on Recursion Pharmaceuticals from $12 to $10, keeping a \"Neutral\" rating on the shares. While acknowledging continued uncertainty in the market, the analyst noted an improved overall health of the biopharma sector compared to the lows of 2022.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Recursion Pharmaceuticals Plunges 5.07% as Analysts Lower Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Recursion Pharmaceuticals Plunges 5.07% as Analysts Lower Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n2025-01-08 22:50 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recursion Pharmaceuticals, Inc. (RXRX) stock saw a significant plummet of 5.07% on Wednesday's intraday trading session. This downward movement in the biopharmaceutical company's stock price appears ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1191372441","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191372441","pubTimestamp":1736347839,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Recursion Pharmaceuticals, Inc.  stock saw a significant plummet of 5.07% on Wednesday's intraday trading session. This downward movement in the biopharmaceutical company's stock price appears to be influenced by analysts lowering their price targets.According to the reports, KeyBanc Capital Markets reduced its price target on RXRX from $12 to $10 while maintaining an \"Overweight\" rating. The firm cited an average rating of \"Overweight\" and a mean price target of $9.17 for the stock, based on an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"分析师下调目标价，Recursion Pharmaceuticals股价暴跌5.07%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"Recursion Pharmaceuticals, Inc. (RXRX) stock saw a significant plummet of 5.07% on Wednesday's intraday trading session. This downward movement in the biopharmaceutical company's stock price appears to be influenced by analysts lowering their price targets.\nAccording to the reports, KeyBanc Capital Markets reduced its price target on RXRX from $12 to $10 while maintaining an \"Overweight\" rating. The firm cited an average rating of \"Overweight\" and a mean price target of $9.17 for the stock, based on analysts polled by FactSet.\nAdditionally, Bank of America analyst Alec Stranahan lowered the firm's price target on Recursion Pharmaceuticals from $12 to $10, keeping a \"Neutral\" rating on the shares. While acknowledging continued uncertainty in the market, the analyst noted an improved overall health of the biopharma sector compared to the lows of 2022.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191372441"}